69674-27-7

Basic information

• Product Name: 6-bromo-4-methylquinazoline
• Synonyms: 6-bromo-4-methylquinazoline
• CAS NO: 69674-27-7
• Molecular Formula: C₉H₇BrN₂
• Molecular Weight: 223.0693
• Mol File: 69674-27-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 320.098 °C at 760 mmHg
• Flash Point: 147.39 °C
• Appearance: /
• Density: 1.566 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.663
• CAS DataBase Reference: 6-bromo-4-methylquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-4-methylquinazoline(69674-27-7)
• EPA Substance Registry System: 6-bromo-4-methylquinazoline(69674-27-7)

Safety Data

• Hazardous Substances Data: 69674-27-7(Hazardous Substances Data)

Usage

General Description

6-Bromo-4-methylquinazoline is a chemical compound that belongs to the quinazoline class of molecules. It is a heterocyclic compound with a bromine atom at position 6 and a methyl group at position 4. Quinazoline derivatives have been studied for their potential pharmaceutical applications, including as antiviral, anticancer, and anti-inflammatory agents. This specific compound may have potential uses in medicinal chemistry and drug development due to its unique structural features and potential biological activities. Additionally, quinazoline derivatives have also been investigated for their use as fluorescent probes and in the synthesis of various organic compounds.

InChI:InChI=1/C9H7BrN2/c1-6-8-4-7(10)2-3-9(8)12-5-11-6/h2-5H,1H3

Upstream product

• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 122-51-0 orthoformic acid triethyl ester 
• 551-93-9 2-aminoacetophenone 
• 463-52-5 formamidine 
• 631-61-8 ammonium acetate 

Downstream Products

• 769916-07-6 C₉H₅BrN₂O₂ 
• 474710-78-6 methyl 6-bromoquinazolin-4-carboxylate 

Relevant articles and documents

SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF

The present application relates to a substituted aryl compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a N-oxide, an isotope-labeled compound, a metabolite or a prodrug thereof, and a preparation method therefor and use thereof, also relates to a pharmaceutical composition containing the compound and a therapeutic use thereof. The compound or a pharmaceutical composition thereof can inhibit the activity of adenosine A2a receptor, and can be used for treating or preventing a disease related to adenosine A2a receptor, especially for treating a tumor.

Aminopyrimidine compound and preparation method and application thereof

The invention relates to an aminopyrimidine compound and a preparation method and application thereof, in particular to an aminopyrimidine compound shown as a formula (I) or pharmaceutically acceptable salts thereof, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug, a pharmaceutical composition containing the compound, a preparation method of the compound and application of the compound to prevention or treatment of adenosine A2a receptor related diseases.

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.